Trials / Completed
CompletedNCT03344094
Mechanism of Action of Ocrelizumab in Multiple Sclerosis
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 30 (actual)
- Sponsor
- University of Chicago · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Accepted
Summary
Ocrelizumab is FDA approved for therapy of multiple sclerosis (MS). It depletes B cells and stops MS inflammation.
Detailed description
The study will investigate immune cell subsets, and how the cells are modified by this therapy over a 1-year period in 25 subjects. Blood will be drawn at baseline, 2 weeks, 6 mo, and 12 mo. Immune subsets will be analyzed by flow cytometry. Data are analyzed with ANOVA with repeated measures.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ocrelizumab | FDA-approved MS drugs |
Timeline
- Start date
- 2018-02-23
- Primary completion
- 2019-04-10
- Completion
- 2019-04-10
- First posted
- 2017-11-17
- Last updated
- 2025-02-21
- Results posted
- 2025-02-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03344094. Inclusion in this directory is not an endorsement.